Lund, SE — September 10, 2025 — Leads & Copy — Alligator Bioscience (Nasdaq Stockholm:ATORX) announced the publication of a peer-reviewed article in Cancer Immunology Research detailing preclinical data on ATOR-4066, a bispecific antibody targeting CD40 and CEACAM5. Developed using Alligator’s Neo-X-Prime™ platform and RUBY™ format, the study, titled “ATOR-4066, a Neo-X-Prime bispecific antibody targeting CD40 and CEACAM5, induces strong myeloid and T cell dependent tumor immunity and synergizes with PD-1 blockade”, demonstrates ATOR-4066’s potential to overcome resistance mechanisms in the tumor microenvironment by inducing localized activation of myeloid cells and T cells within the tumor while sparing healthy tissues.
Key findings include tumor-localized activation of CD40 in human tumor samples, strong anti-tumor activity even in tumors with heterogenous CEACAM5 expression, activation of the immune system in the tumor resulting in tumor rejection, and synergistic activity with anti-PD-1 treatment.
Søren Bregenholt, CEO of Alligator Bioscience, stated that the publication underscores the potential of the Neo-X-Prime platform and RUBY format. ATOR-4066 represents a promising therapeutic strategy for CEACAM5-expressing tumors and further demonstrates Alligator’s strength in developing tumor-targeted CD40 agonists.
Søren Bregenholt, CEO, can be reached at soren.bregenholt@alligatorbioscience.com or +46 (0) 46 540 82 00.
